EPPS rescues hippocampus-dependent cognitive deficits in APP/PS1 mice by disaggregation of amyloid-β oligomers and plaques
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, H.Y. | - |
dc.contributor.author | Kim, H.V. | - |
dc.contributor.author | Jo, S. | - |
dc.contributor.author | Lee, C.J. | - |
dc.contributor.author | Choi, S.Y. | - |
dc.contributor.author | Kim, D.J. | - |
dc.contributor.author | Kim, Y. | - |
dc.date.accessioned | 2021-09-05T00:00:10Z | - |
dc.date.available | 2021-09-05T00:00:10Z | - |
dc.date.created | 2021-06-17 | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 2041-1723 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/95946 | - |
dc.description.abstract | Alzheimer's disease (AD) is characterized by the transition of amyloid-β (Aβ) monomers into toxic oligomers and plaques. Given that Aβ abnormality typically precedes the development of clinical symptoms, an agent capable of disaggregating existing Aβ aggregates may be advantageous. Here we report that a small molecule, 4-(2-hydroxyethyl)-1-piperazinepropanesulphonic acid (EPPS), binds to Aβ aggregates and converts them into monomers. The oral administration of EPPS substantially reduces hippocampus-dependent behavioural deficits, brain Aβ oligomer and plaque deposits, glial 3-aminobutyric acid (GABA) release and brain inflammation in an Aβ-overexpressing, APP/PS1 transgenic mouse model when initiated after the development of severe AD-like phenotypes. The ability of EPPS to rescue Aβ aggregation and behavioural deficits provides strong support for the view that the accumulation of Aβ is an important mechanism underlying AD. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | Nature Publishing Group | - |
dc.subject | 4 (2 hydroxyethyl) 1 piperazinepropanesulphonic acid | - |
dc.subject | 4 aminobutyric acid | - |
dc.subject | amyloid beta protein | - |
dc.subject | amyloid precursor protein | - |
dc.subject | central nervous system agents | - |
dc.subject | oligomer | - |
dc.subject | presenilin 1 | - |
dc.subject | unclassified drug | - |
dc.subject | amyloid precursor protein | - |
dc.subject | N(2-hydroxythyl)piperazine-N&apos | - |
dc.subject | -(3-propanesulfonic acid) | - |
dc.subject | piperazine derivative | - |
dc.subject | presenilin 1 | - |
dc.subject | acid | - |
dc.subject | brain | - |
dc.subject | cognition | - |
dc.subject | experimental study | - |
dc.subject | nervous system disorder | - |
dc.subject | phenotype | - |
dc.subject | rodent | - |
dc.subject | 4 aminobutyric acid release | - |
dc.subject | Alzheimer disease | - |
dc.subject | amyloid plaque | - |
dc.subject | animal experiment | - |
dc.subject | animal model | - |
dc.subject | animal tissue | - |
dc.subject | Article | - |
dc.subject | blood brain barrier | - |
dc.subject | cognitive defect | - |
dc.subject | controlled study | - |
dc.subject | disease severity | - |
dc.subject | drug blood level | - |
dc.subject | drug brain level | - |
dc.subject | drug mechanism | - |
dc.subject | drug penetration | - |
dc.subject | drug protein binding | - |
dc.subject | hippocampus | - |
dc.subject | inflammation | - |
dc.subject | male | - |
dc.subject | mouse | - |
dc.subject | nonhuman | - |
dc.subject | phase 3 clinical trial | - |
dc.subject | phenotype | - |
dc.subject | protein aggregation | - |
dc.subject | protein expression | - |
dc.subject | Alzheimer disease | - |
dc.subject | amyloid plaque | - |
dc.subject | animal | - |
dc.subject | cognition | - |
dc.subject | deficiency | - |
dc.subject | disease model | - |
dc.subject | drug effects | - |
dc.subject | genetics | - |
dc.subject | hippocampus | - |
dc.subject | human | - |
dc.subject | Institute for Cancer Research mouse | - |
dc.subject | metabolism | - |
dc.subject | psychology | - |
dc.subject | transgenic mouse | - |
dc.subject | Mus | - |
dc.subject | Mus musculus | - |
dc.subject | Alzheimer Disease | - |
dc.subject | Amyloid beta-Protein Precursor | - |
dc.subject | Animals | - |
dc.subject | Cognition | - |
dc.subject | Disease Models, Animal | - |
dc.subject | Hippocampus | - |
dc.subject | Humans | - |
dc.subject | Male | - |
dc.subject | Mice | - |
dc.subject | Mice, Inbred ICR | - |
dc.subject | Mice, Transgenic | - |
dc.subject | Piperazines | - |
dc.subject | Plaque, Amyloid | - |
dc.subject | Presenilin-1 | - |
dc.title | EPPS rescues hippocampus-dependent cognitive deficits in APP/PS1 mice by disaggregation of amyloid-β oligomers and plaques | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, C.J. | - |
dc.identifier.doi | 10.1038/ncomms9997 | - |
dc.identifier.scopusid | 2-s2.0-84949599389 | - |
dc.identifier.bibliographicCitation | Nature Communications, v.6 | - |
dc.relation.isPartOf | Nature Communications | - |
dc.citation.title | Nature Communications | - |
dc.citation.volume | 6 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.subject.keywordPlus | 4 (2 hydroxyethyl) 1 piperazinepropanesulphonic acid | - |
dc.subject.keywordPlus | 4 aminobutyric acid | - |
dc.subject.keywordPlus | amyloid beta protein | - |
dc.subject.keywordPlus | amyloid precursor protein | - |
dc.subject.keywordPlus | central nervous system agents | - |
dc.subject.keywordPlus | oligomer | - |
dc.subject.keywordPlus | presenilin 1 | - |
dc.subject.keywordPlus | unclassified drug | - |
dc.subject.keywordPlus | amyloid precursor protein | - |
dc.subject.keywordPlus | N(2-hydroxythyl)piperazine-N&apos | - |
dc.subject.keywordPlus | -(3-propanesulfonic acid) | - |
dc.subject.keywordPlus | piperazine derivative | - |
dc.subject.keywordPlus | presenilin 1 | - |
dc.subject.keywordPlus | acid | - |
dc.subject.keywordPlus | brain | - |
dc.subject.keywordPlus | cognition | - |
dc.subject.keywordPlus | experimental study | - |
dc.subject.keywordPlus | nervous system disorder | - |
dc.subject.keywordPlus | phenotype | - |
dc.subject.keywordPlus | rodent | - |
dc.subject.keywordPlus | 4 aminobutyric acid release | - |
dc.subject.keywordPlus | Alzheimer disease | - |
dc.subject.keywordPlus | amyloid plaque | - |
dc.subject.keywordPlus | animal experiment | - |
dc.subject.keywordPlus | animal model | - |
dc.subject.keywordPlus | animal tissue | - |
dc.subject.keywordPlus | Article | - |
dc.subject.keywordPlus | blood brain barrier | - |
dc.subject.keywordPlus | cognitive defect | - |
dc.subject.keywordPlus | controlled study | - |
dc.subject.keywordPlus | disease severity | - |
dc.subject.keywordPlus | drug blood level | - |
dc.subject.keywordPlus | drug brain level | - |
dc.subject.keywordPlus | drug mechanism | - |
dc.subject.keywordPlus | drug penetration | - |
dc.subject.keywordPlus | drug protein binding | - |
dc.subject.keywordPlus | hippocampus | - |
dc.subject.keywordPlus | inflammation | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | mouse | - |
dc.subject.keywordPlus | nonhuman | - |
dc.subject.keywordPlus | phase 3 clinical trial | - |
dc.subject.keywordPlus | phenotype | - |
dc.subject.keywordPlus | protein aggregation | - |
dc.subject.keywordPlus | protein expression | - |
dc.subject.keywordPlus | Alzheimer disease | - |
dc.subject.keywordPlus | amyloid plaque | - |
dc.subject.keywordPlus | animal | - |
dc.subject.keywordPlus | cognition | - |
dc.subject.keywordPlus | deficiency | - |
dc.subject.keywordPlus | disease model | - |
dc.subject.keywordPlus | drug effects | - |
dc.subject.keywordPlus | genetics | - |
dc.subject.keywordPlus | hippocampus | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | Institute for Cancer Research mouse | - |
dc.subject.keywordPlus | metabolism | - |
dc.subject.keywordPlus | psychology | - |
dc.subject.keywordPlus | transgenic mouse | - |
dc.subject.keywordPlus | Mus | - |
dc.subject.keywordPlus | Mus musculus | - |
dc.subject.keywordPlus | Alzheimer Disease | - |
dc.subject.keywordPlus | Amyloid beta-Protein Precursor | - |
dc.subject.keywordPlus | Animals | - |
dc.subject.keywordPlus | Cognition | - |
dc.subject.keywordPlus | Disease Models, Animal | - |
dc.subject.keywordPlus | Hippocampus | - |
dc.subject.keywordPlus | Humans | - |
dc.subject.keywordPlus | Male | - |
dc.subject.keywordPlus | Mice | - |
dc.subject.keywordPlus | Mice, Inbred ICR | - |
dc.subject.keywordPlus | Mice, Transgenic | - |
dc.subject.keywordPlus | Piperazines | - |
dc.subject.keywordPlus | Plaque, Amyloid | - |
dc.subject.keywordPlus | Presenilin-1 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.